Samuel Meyers, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: The experience of Kozarek and colleagues (1) with methotrexate in the therapy of inflammatory bowel disease is novel and should be pursued. However, a preliminary uncontrolled report including only a few patients is not acceptable. The types of patients studied were variable and the other components of their therapy were not standardized. Certainly the enthusiasm of the investigators and the knowledge that the patients were being studied with a new drug must have influenced the outcome. This possibility is especially true in inflammatory bowel disease which is so difficult to measure.
It has been previously shown (2)
Meyers S. Methotrexate and Inflammatory Bowel Disease. Ann Intern Med. ;110:845. doi: 10.7326/0003-4819-110-10-845_1
Download citation file:
Published: Ann Intern Med. 1989;110(10):845.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use